

Resource Summary Report

Generated by [dkNET](#) on Sep 2, 2026

SNU-182

RRID:CVCL_0090

Type: Cell Line

Proper Citation

RRID:CVCL_0090

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0090

Proper Citation: RRID:CVCL_0090

Description: Cell line SNU-182 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Adult hepatocellular carcinoma

Defining Citation: [PMID:7543080](#), [PMID:8824565](#), [PMID:19956504](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:23505090](#), [PMID:23887712](#), [PMID:25485619](#), [PMID:25574106](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:31063779](#), [PMID:31068700](#), [PMID:31378681](#)

Comments: Population: Korean., Part of: Seoul National University (SNU) cell line collection., Part of: Liver Cancer Model Repository (LIMORE)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SNU-182

Synonyms: SNU182, NCI-SNU-182

Cross References: BTO:BTO_0003760, CLO:CLO_0009096, EFO:EFO_0002345, AddexBio:C0015003/4954, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2235, BioSample:SAMN03473221, BioSample:SAMN10987895, cancercellines:CVCL_0090, CCRID:3101HUMSCSP5047, Cell_Model_Passport:SIDM01151, ChEMBL-

Cells:CHEMBL4295423, ChEMBL-Targets:CHEMBL4296495, CLS:305119, Cosmic:684198, Cosmic:873399, Cosmic:928141, Cosmic:1995638, Cosmic:2162540, Cosmic:2321040, Cosmic-CLP:1240216, DepMap:ACH-000483, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1240216, GEO:GSM481446, GEO:GSM565919, GEO:GSM887613, GEO:GSM888697, GEO:GSM936778, GEO:GSM1670465, GEO:GSM2551583, IARC_TP53:6304, IGRhCellID:SNU182, KCLB:00182, LiGeA:CCLE_348, LIMORE:SNU182, LINCS_LDP:LCL-1932, PharmacDB:SNU182_1448_2019, Progenetix:CVCL_0090, PubChem_Cell_line:CVCL_0090, Wikidata:Q54955141

ID: CVCL_0090

Record Creation Time: 20220427T221551+0000

Record Last Update: 20260829T235946+0000

Ratings and Alerts

No rating or validation information has been found for SNU-182.

No alerts have been found for SNU-182.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Lee J, et al. (2026) Dammarenediol II enhances etoposide-induced apoptosis by targeting O-GlcNAc transferase and Akt/GSK3 β /mTOR signaling in liver cancer. Molecular oncology, 20(6), 1591.

Chen L, et al. (2026) Sex-specific KDM6A-HNF4A-CREBH network controls lipoprotein cholesterol metabolism and atherosclerosis via epigenetic reprogramming of hepatocytes. Nature communications, 17(1).

Turnham RE, et al. (2025) HBV Remodels PP2A Complexes to Rewire Kinase Signaling in Hepatocellular Carcinoma. Cancer research, 85(4), 660.

Li X, et al. (2025) IFN γ augments TKI efficacy by alleviating protein unfolding stress to promote GSDME-mediated pyroptosis in hepatocellular carcinoma. Cell death & disease, 16(1), 512.

Mesropian A, et al. (2025) E7386 Enhances Lenvatinib's Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(23), 5037.

Jinesh GG, et al. (2024) C19MC drives nucleolar invasion of mitochondria and meiotic nuclear division in human cancers. *iScience*, 27(11), 111132.

Zhang J, et al. (2023) PSMD4 drives progression of hepatocellular carcinoma via Akt/COX2 pathway and p53 inhibition. *Human cell*, 36(5), 1755.

Zhang Q, et al. (2023) Hypoxia-Responsive lncRNA AC115619 Encodes a Micropeptide That Suppresses m6A Modifications and Hepatocellular Carcinoma Progression. *Cancer research*, 83(15), 2496.

Xie W, et al. (2023) SYVN1 ubiquitinates FoxO1 to induce β -catenin nuclear translocation, PD-L1-mediated metastasis, and immune evasion of hepatocellular carcinoma. *Cellular oncology (Dordrecht)*.

Missiaen R, et al. (2022) GCN2 inhibition sensitizes arginine-deprived hepatocellular carcinoma cells to senolytic treatment. *Cell metabolism*, 34(8), 1151.

Wehling L, et al. (2022) Spatial modeling reveals nuclear phosphorylation and subcellular shuttling of YAP upon drug-induced liver injury. *eLife*, 11.